Your CMO partner for viral vector GMP manufacturing
ABL Europe SAS is a pure-play GMP CMO, completely dedicated to the provision of viral vector GMP contract manufacturing services and a subsidiary of ABL Inc. under the corporate (private) ownership of Institut Mérieux. Formed by the acquisition of Transgene’s GMP manufacturing facilities, ABL has a particularly strong technical & regulatory track record in process development, scale-up & GMP manufacturing of oncolytic and immunotherapeutic viral vectors.
With drug substance, drug product & comprehensive QC testing capabilities in-house, ABL supports biotech and pharma companies in all phases of clinical development and is currently supporting different clients with process validation and GMP supply of oncolytic viral vectors for phase 3 / pivotal efficacy studies being performed globally. Hence, ABL has first-hand experience and understands the regulatory expectations for expanding the chemistry, manufacturing and controls (CMC) content for viral vector therapies used in all stages of clinical development and late stage pivotal studies.
With the acquisition of a manufacturing site in Lyon in 2018, ABL Europe has strengthened its position in the GMP viral vector CMO market to support clients with a long term manufacturing strategy able to meet their clinical development & product registration objectives.